We are live on ! Find out more
TVTX icon

Travere Therapeutics
TVTX

175 hedge funds and large institutions have $677M invested in Travere Therapeutics in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 64 increasing their positions, 48 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 21

33% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 48

6% more funds holding

Funds holding: 165 → 175 (+10)

4.07% less ownership

Funds ownership: 119.41% → 115.35% (-4.1%)

16% less capital invested

Capital invested by funds: $807M → $677M (-$129M)

81% less call options, than puts

Call options by funds: $1.09M | Put options by funds: $5.82M

Holders
175
Holders Change
+10
Holders Change %
+6.06%
% of All Funds
2.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
64
Reduced
48
Closed
21
Calls
$1.09M
Puts
$5.82M
Net Calls
-$4.73M
Net Calls Change
+$1.55M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$10.6M
2
EP
Eversept Partners
New York
+$8.06M
3
Millennium Management
Millennium Management
New York
+$7.65M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$7.36M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$6.33M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$40M
2
FCM
Farallon Capital Management
California
-$9.84M
3
APM
Avidity Partners Management
Texas
-$7.43M
4
Goldman Sachs
Goldman Sachs
New York
-$6.51M
5
WP
Woodline Partners
California
-$5.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
US Bancorp
151
US Bancorp
Minnesota
$7.08K +$2.56K +303 +49%
Ohio Public Employees Retirement System (OPERS)
152
Ohio Public Employees Retirement System (OPERS)
Ohio
$6.01K -$431K -51,126 -98%
Comerica Bank
153
Comerica Bank
Texas
$3.62K -$1.28K -152 -24%
LC
154
Lindbrook Capital
California
$3.36K +$3.68K +436 New
NS
155
NBC Securities
Alabama
$3K – – –
National Bank of Canada
156
National Bank of Canada
Quebec, Canada
$2.52K – – –
HT
157
Headlands Technologies
Illinois
$2.33K -$19.5K -2,309 -88%
PA
158
Parallel Advisors
California
$2.21K – – –
Daiwa Securities Group
159
Daiwa Securities Group
Japan
$2K – – –
MPWT
160
MassMutual Private Wealth & Trust
Connecticut
$1.81K – – –
FFA
161
Farther Finance Advisors
California
$1.06K – – –
ACM
162
ADAR1 Capital Management
Texas
$771 – – –
SWS
163
SYSTM Wealth Solutions
Illinois
$509 – – –
VCM
164
Versant Capital Management
Arizona
$470 +$515 +61 New
SAM
165
Smartleaf Asset Management
Massachusetts
$460 +$506 +60 New
PWMG
166
Private Wealth Management Group
New Jersey
$448 – – –
Northwestern Mutual Wealth Management
167
Northwestern Mutual Wealth Management
Wisconsin
$301 +$329 +39 New
GI
168
GAMMA Investing
California
$231 +$253 +30 New
Osaic Holdings
169
Osaic Holdings
Arizona
$177 – – –
GRP
170
Global Retirement Partners
California
$146 – – –
RIL
171
Rothschild Investment LLC
Illinois
$116 +$127 +15 New
AWM
172
Avior Wealth Management
Nebraska
$107 +$118 +14 New
Toronto Dominion Bank
173
Toronto Dominion Bank
Ontario, Canada
$23 – – –
FCM
174
Farallon Capital Management
California
– -$9.84M -1,094,000 Closed
APM
175
Avidity Partners Management
Texas
– -$7.43M -827,010 Closed
4 5 6
7
8

TVTX Hedge Fund Activity: Q1 2024 in Review

175 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2024, worth a combined $677M — down 16% from $807M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new TVTX positions and 21 closed out — a net gain of 10 holders — while 64 added to existing stakes and 48 trimmed.

The largest buyer was State Street, adding an estimated $10.6M. The largest seller was Morgan Stanley, cutting an estimated $40M.

  • 175 institutional investors held Travere Therapeutics (TVTX) as of Q1 2024, up from 165 in Q4 2023.
  • Funds reported $677M of Travere Therapeutics stock for Q1 2024, down 16% quarter-over-quarter.
  • 31 funds opened new Travere Therapeutics positions in Q1 2024 and 21 closed out, a net change of +10 holders.
  • The largest Travere Therapeutics buyer in Q1 2024 was State Street, an estimated $10.6M added.
  • The largest Travere Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $40M sold.

Based on aggregated 13F filings for Q1 2024.